🚀 VC round data is live in beta, check it out!

Aurisco Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Aurisco Pharmaceutical and similar public comparables like AbCellera, Sino Biological, Fortrea, Jubilant Pharmova and more.

Aurisco Pharmaceutical Overview

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.


Founded

1998

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $261M
EBITDA: $105M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Aurisco Pharmaceutical Financials

Aurisco Pharmaceutical reported last 12-month revenue of $261M and EBITDA of $105M.

In the same LTM period, Aurisco Pharmaceutical generated $153M in gross profit, $105M in EBITDA, and $67M in net income.

Revenue (LTM)


Aurisco Pharmaceutical P&L

In the most recent fiscal year, Aurisco Pharmaceutical reported revenue of $249M and EBITDA of $99M.

Aurisco Pharmaceutical is profitable as of last fiscal year, with gross margin of 60%, EBITDA margin of 40%, and net margin of 26%.

See analyst estimates for Aurisco Pharmaceutical
LTMLast FY202320242025202620272028
Revenue$261M$249M$185M$216M$249M
Gross Profit$153M$148M$103M$127M$148M
Gross Margin59%60%56%59%60%
EBITDA$105M$99M$60M$75M$99M
EBITDA Margin40%40%33%35%40%
EBIT Margin30%33%23%28%33%
Net Profit$67M$66M$42M$52M$66M
Net Margin26%26%23%24%26%
Net Debt—$21M———

Financial data powered by Morningstar, Inc.

Aurisco Pharmaceutical Stock Performance

Aurisco Pharmaceutical has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


Aurisco Pharmaceutical's stock price is $3.31.

Aurisco Pharmaceutical share price increased by 0.1% in the last 30 days, and by 8.3% in the last year.

Aurisco Pharmaceutical has an EPS (earnings per share) of $0.16.

See more trading valuation data for Aurisco Pharmaceutical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B0.1%0.1%-15.0%8.3%$0.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Aurisco Pharmaceutical Valuation Multiples

Aurisco Pharmaceutical trades at 5.2x EV/Revenue multiple, and 12.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Aurisco Pharmaceutical

EV / Revenue (LTM)


Aurisco Pharmaceutical Financial Valuation Multiples

As of May 2, 2026, Aurisco Pharmaceutical has market cap of $1B and EV of $1B.

Aurisco Pharmaceutical has a P/E ratio of 20.0x.

LTMLast FY202320242025202620272028
EV/Revenue5.2x5.5x7.3x6.3x5.5x
EV/EBITDA12.9x13.6x22.5x18.1x13.6x
EV/EBIT17.4x16.5x31.2x22.5x16.5x
EV/Gross Profit8.9x9.1x13.1x10.7x9.1x
P/E20.0x20.4x31.7x25.9x20.4x
EV/FCF—129.6x115.5x(44.5x)129.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Aurisco Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Aurisco Pharmaceutical Margins & Growth Rates

Aurisco Pharmaceutical grew revenue by 15% and EBITDA by 19% in the last fiscal year.

In the most recent fiscal year, Aurisco Pharmaceutical reported gross margin of 60%, EBITDA margin of 40%, and net margin of 26%.

See estimated margins and future growth rates for Aurisco Pharmaceutical

Aurisco Pharmaceutical Margins

Last FY202420252026202720282029
Gross Margin60%59%60%57%
EBITDA Margin40%35%40%42%
EBIT Margin33%28%33%28%
Net Margin26%24%26%25%
FCF Margin4%(14%)4%—

Aurisco Pharmaceutical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth15%17%15%15%
Gross Profit Growth9%22%17%9%
EBITDA Growth19%24%33%19%
EBIT Growth(1%)39%36%(1%)
Net Profit Growth7%23%27%7%
FCF Growth—(359%)(134%)—

Data powered by FactSet, Inc. and Morningstar, Inc.

Aurisco Pharmaceutical Operational KPIs

Aurisco Pharmaceutical's Rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Aurisco Pharmaceutical's Rule of X is 79% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Aurisco Pharmaceutical
LTMLast FY202320242025202620272028
Rule of 4054%57%———
Bessemer Rule of X75%79%———
S&M Expenses to Revenue7%8%6%7%6%
G&A Expenses to Revenue10%10%6%5%3%
R&D Expenses to Revenue9%9%11%10%9%
Opex to Revenue—27%32%31%27%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Aurisco Pharmaceutical Competitors

Aurisco Pharmaceutical competitors include AbCellera, Sino Biological, Fortrea, Jubilant Pharmova, ACROBiosystems, Evotec, PolyPeptide, Bora Pharmaceuticals, Oxford BioMedica and R&G PharmaStudies.

Most Aurisco Pharmaceutical public comparables operate across Contract Research & Manufacturing, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
AbCellera12.8x16.0x(5.5x)(4.5x)
Sino Biological7.8x—20.0x—
Fortrea0.8x0.8x11.0x10.8x
Jubilant Pharmova2.1x2.0x10.7x13.3x
ACROBiosystems7.4x6.8x26.0x24.0x
Evotec1.2x1.2x22.1x24.0x
PolyPeptide3.7x3.4x32.5x25.3x
Bora Pharmaceuticals3.4x3.2x9.5x9.2x

This data is available for Pro users. Sign up to see all Aurisco Pharmaceutical competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Aurisco Pharmaceutical

When was Aurisco Pharmaceutical founded?Aurisco Pharmaceutical was founded in 1998.
Where is Aurisco Pharmaceutical headquartered?Aurisco Pharmaceutical is headquartered in China.
Is Aurisco Pharmaceutical publicly listed?Yes, Aurisco Pharmaceutical is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Aurisco Pharmaceutical?Aurisco Pharmaceutical trades under 605116 ticker.
When did Aurisco Pharmaceutical go public?Aurisco Pharmaceutical went public in 2020.
Who are competitors of Aurisco Pharmaceutical?Aurisco Pharmaceutical main competitors include AbCellera, Sino Biological, Fortrea, Jubilant Pharmova, ACROBiosystems, Evotec, PolyPeptide, Bora Pharmaceuticals, Oxford BioMedica, R&G PharmaStudies.
What is the current market cap of Aurisco Pharmaceutical?Aurisco Pharmaceutical's current market cap is $1B.
What is the current revenue of Aurisco Pharmaceutical?Aurisco Pharmaceutical's last 12 months revenue is $261M.
What is the current revenue growth of Aurisco Pharmaceutical?Aurisco Pharmaceutical revenue growth (NTM/LTM) is 14%.
What is the current EV/Revenue multiple of Aurisco Pharmaceutical?Current revenue multiple of Aurisco Pharmaceutical is 5.2x.
Is Aurisco Pharmaceutical profitable?Yes, Aurisco Pharmaceutical is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Aurisco Pharmaceutical?Aurisco Pharmaceutical's last 12 months EBITDA is $105M.
What is Aurisco Pharmaceutical's EBITDA margin?Aurisco Pharmaceutical's last 12 months EBITDA margin is 40%.
What is the current EV/EBITDA multiple of Aurisco Pharmaceutical?Current EBITDA multiple of Aurisco Pharmaceutical is 12.9x.
How many companies Aurisco Pharmaceutical has acquired to date?Aurisco Pharmaceutical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Aurisco Pharmaceutical has invested to date?Aurisco Pharmaceutical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Aurisco Pharmaceutical

Lists including Aurisco Pharmaceutical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial